Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Inflammatory Bowel Diseases

• Publication date

  2012-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ibd.22940PMID 22419649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.

  2010cited by this paper
• The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

  2009influential reference
• Mucosal addressin cell-adhesion molecule-1 controls plasma-cell migration and function in the small intestine of mice.

  2009cited by this paper
• Immunotoxicity profile of natalizumab

  2009cited by this paper
• Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

  2008cited by this paper
• Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

  2008cited by this paper
• Distinct changes in adult lymphopoiesis in Rag2-/- mice fully reconstituted by alpha4-deficient adult bone marrow cells.

  2008cited by this paper
• 703 Gut-Homing CD4+ Lymphocytes Are Specifically Targeted in Cynomolgus Monkeys Dosed with Anti-Beta7 Antibodies

  2008cited by this paper
• The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.

  2008cited by this paper
• Unravelling the pathogenesis of inflammatory bowel disease

  2007cited by this paper
• Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

  2007cited by this paper
• Tissue-tropic effector T cells: generation and targeting opportunities

  2006cited by this paper
• Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

  2005cited by this paper
• Natalizumab induction and maintenance therapy for Crohn's disease.

  2005cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003cited by this paper
• Natalizumab for active Crohn's disease.

  2003cited by this paper
• Alpha4 integrins as therapeutic targets in autoimmune disease.

  2003cited by this paper
• Beta1 integrin is not essential for hematopoiesis but is necessary for the T cell-dependent IgM antibody response.

  2002cited by this paper
• Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7.

  1996cited by this paper

• Long-Term Outcomes and Prognostic Factors for Vedolizumab-Treated Japanese Patients with Ulcerative Colitis

  2025cites this paper
• The Role and Application of MAdCAM-1/α4β7-Induced Lymphocyte Migration in Inflammatory Enterohepatic Diseases

  2025cites this paper
• Recent Development in Celiac Disease: Pathophysiology, Animal Models and Treatments

  2025cites this paper
• The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis

  2025cites this paper
• Unraveling the role of γδ T cells in inflammatory bowel disease: Development and prevention strategies.

  2025cites this paper
• A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.

  2025cites this paper
• Physicochemical and biological stability of diluted vedolizumab in intravenous infusion bags

  2024cites this paper
• MicroRNA signatures in the pathogenesis and therapy of inflammatory bowel disease

  2024cites this paper
• Lymphocyte subsets for predicting inflammatory bowel disease progression and treatment response: a systematic review

  2024cites this paper
• Development and Validation of a Scoring System to Predict 2-Year Clinical Remission in Ulcerative Colitis Patients on Vedolizumab

  2024cites this paper
• Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4+ T cells as predictors for response to integrin α4β7-blocking therapy in inflammatory bowel disease.

  2024cites this paper
• The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group

  2024cites this paper
• Targeting T-cell integrins in autoimmune and inflammatory diseases.

  2023cites this paper
• Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy

  2023cites this paper
• Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques

  2023cites this paper
• Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.

  2023cites this paper
• Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future

  2023cites this paper
• An electrospun macrodevice for durable encapsulation of human cells with consistent secretion of therapeutic antibodies.

  2023cites this paper
• Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease

  2023cites this paper
• Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis

  2023cites this paper
• Successful treatment of a refractory intestinal Behcet’s disease with an oncology history by Vedolizumab: a case report and literature review

  2023cites this paper
• Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study

  2023cites this paper
• Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis

  2023cites this paper
• Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis

  2022cites this paper
• Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis

  2022cites this paper
• Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?

  2022cites this paper
• Eosinophilic esophagitis: from pathophysiology to management

  2022cites this paper
• Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease

  2022cites this paper
• A Computational Platform Integrating a Mechanistic Model of Crohn’s Disease for Predicting Temporal Progression of Mucosal Damage and Healing

  2022cites this paper
• Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Systematic review and meta‐analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease

  2021cites this paper
• MicroRNA expression in inflammatory bowel disease-associated colorectal cancer

  2021cites this paper
• Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study

  2021cites this paper
• Visualization of integrin molecules by fluorescence imaging and techniques

  2021cites this paper
• Progress in research of vedolizumab in treatment of inflammatory bowel disease

  2021cites this paper
• Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development

  2021cites this paper
• Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease

  2021cites this paper
• Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.

  2021cites this paper
• T-Cell Adhesion in Healthy and Inflamed Skin

  2021cites this paper
• Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab

  2020cites this paper
• Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease

  2020cites this paper
• Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy

  2020cites this paper
• Targeted Therapies for Eosinophilic Gastrointestinal Disorders

  2020cites this paper
• Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases

  2020cites this paper
• Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

  2020cites this paper
• Biologic Therapy for Ulcerative Colitis.

  2020cites this paper
• MicroRNA Biomarkers in IBD—Differential Diagnosis and Prediction of Colitis-Associated Cancer

  2020cites this paper
• Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment

  2020cites this paper
• CE_A_179053 7..20

  2020cites this paper
• Eosinophilic esophagitis and biologics.

  2020cites this paper
• Medikamentöse Therapie der Colitis ulcerosa und Pouchitis

  2020cites this paper
• Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?

  2020cites this paper
• Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience

  2019cites this paper
• The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti‐integrin therapies

  2019cites this paper
• A product review of vedolizumab in inflammatory bowel disease

  2019cites this paper
• Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?

  2019cites this paper
• Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case–control study

  2019cites this paper
• Characterization of γδ T cells in intestinal mucosa from patients with early onset or long standing inflammatory bowel disease and their correlation with clinical status.

  2019cites this paper
• Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis

  2019cites this paper
• Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

  2019cites this paper
• Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.

  2019cites this paper
• Medical Management of Chronic Ulcerative Colitis

  2019cites this paper
• Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn’s Disease and Ulcerative Colitis

  2018cites this paper
• Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report.

  2018cites this paper
• Human γδ T-Cell Control of Mucosal Immunity and Inflammation

  2018cites this paper
• The eosinophil: For better or worse, in sickness and in health.

  2018cites this paper
• A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials

  2018cites this paper
• Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques

  2018influential citation
• Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn’s Disease at a Tertiary Referral Center

  2018cites this paper
• Selectively targeting the gut in inflammatory bowel disease: Targeting integrins

  2018cites this paper
• Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals

  2018cites this paper
• Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

  2018cites this paper
• Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

  2018cites this paper
• Anti-integrin Agents in IBD: Efficacy and Risk of Complications

  2018cites this paper
• What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?

  2018cites this paper
• A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab

  2017cites this paper
• Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease

  2017cites this paper
• Emerging biologics in inflammatory bowel disease

  2017cites this paper
• Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

  2017cites this paper
• The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease

  2017cites this paper
• Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

  2017cites this paper
• Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?

  2017cites this paper
• Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.

  2017cites this paper
• Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A

  2017cites this paper
• Simultaneous inhibition of α4/β7 integrin and tumour necrosis factor-α in concomitant spondyloarthritis and inflammatory bowel disease

  2017cites this paper
• Update on the Use of Biologic Therapy in Ulcerative Colitis

  2017cites this paper
• Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab

  2017cites this paper
• Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

  2017cites this paper
• Protein Therapeutics in Autoimmune and Inflammatory Diseases

  2017cites this paper
• Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use

  2016cites this paper
• Preventive health measures in inflammatory bowel disease

  2016cites this paper
• Long-term Efficacy of Vedolizumab for Crohn’s Disease

  2016cites this paper
• Leukocyte Trafficking to the Small Intestine and Colon.

  2016cites this paper
• Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab

  2016cites this paper
• An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.

  2016cites this paper
• Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis

  2016cites this paper
• Vedolizumab for the treatment of ulcerative colitis

  2016cites this paper
• Progress in the Diagnosis and Management of Inflammatory Bowel Disease

  2016cites this paper
• Long-term Efficacy of Vedolizumab for Ulcerative Colitis

  2016cites this paper
• Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use

  2016cites this paper